Our Focus
For the 123 million US adults who have presbyopia, we are in pursuit of restoring the near vision of youth, enabling the freedom of experiencing life without using glasses or contact lenses.
Visus Therapeutics™ is a clinical-stage company dedicated to dramatically improving patient lives by developing differentiated, best-in-class ophthalmic therapies.
And we're just getting started...
DISCOVER OUR PIPELINE TODAY
With officies in Seattle and Orange County, Visus is home to our lead clinical candidate, BRIMOCHOL™ (carbachol + brimonidine tartrate), an eye drop being evaluated to correct the loss of near vision associated with presbyopia.
For the 123 million US adults who have presbyopia, we are in pursuit of restoring the near vision of youth, enabling the freedom of experiencing life without using glasses or contact lenses.
Presbyopia is the gradual loss of near vision associated with aging. It is a normal part of the aging process, usually first noticed by adults in their 40s and 50s. Typically, the first symptom of presbyopia is the tendency to hold reading materials, such as a restaurant menu or a medication label, farther away. Over time, it gets harder to see objects at an intermediate distance, like a computer screen or labels on a store shelf. Reading glasses or bifocals are the most common correction for presbyopia. Without using some type of correction people may experience blurred vision, eye strain, or headaches.
The clear lens in the eye focuses light onto the retina. In younger people, the lens is soft and flexible, and changes shape easily, which is what allows us to shift focus between near and distant objects. As we age, the lens becomes more rigid and isn’t able to change shape as easily, making it more difficult to focus up close.
Visus Therapeutics is dedicated to helping the billions of adults who suffer from presbyopia through the development of its investigational medicine, BRIMOCHOL™.
© VISUS THERAPEUTICS 2021 ALL RIGHTS RESERVED
VISUS THERAPEUTICS and BRIMOCHOL are trademarks of Visus Therapeutics, Inc.